Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionIHT Wealth Management, LLC
Latest Disclosed Ownership1,697 shares
Latest Disclosed Value $ 757,790
IHT Wealth Management, LLC reports 15.99% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - IHT Wealth Management, LLC filed a 13F-HR form disclosing ownership of 1,697 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $757,778 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,463 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 15.99% during the quarter. The current value of the position is $726,893 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,697 234 15.99 758 14.18 0.0175
2026-02-17 2025-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,463 -79 -5.12 663 9.95 0.0161
2025-11-14 2025-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,542 -5 -0.32 604 -12.35 0.0153
2025-08-14 2025-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,547 5 0.32 689 -7.90 0.0189
2025-05-15 2025-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,542 -242 -13.57 747 4.04 0.0233
2025-02-14 2024-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,784 -747 -29.51 718 -39.15 0.0232
2024-11-14 2024-09-30 13F Vertex Pharmaceuticals COM 92532F100 2,531 467 22.63 1,180 22.03 0.0335
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,064 -51 -2.41 967 9.39 0.0361
2024-05-15 2024-03-31 13F Vertex Pharmaceuticals COM 92532F100 2,115 337 18.95 884 22.27 0.0354
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,778 36 2.07 723 19.50 0.0323
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,742 -60 -3.33 606 -4.57 0.0307
2023-08-15 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,802 -141 -7.26 634 3.59 0.0330
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,943 -70 -3.48 612 5.34 0.0349
2023-02-15 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,013 -212 -9.53 581 -9.78 0.0365
2022-11-22 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,225 2,225 644 0.0489
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,838 -100.00 0 -100.00
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,838 -2,428 -56.92 480 -48.77 0.0364
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,266 -522 -10.90 937 7.95 0.0691
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,788 -1,459 -23.36 868 -31.11 0.0707
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,247 619 11.00 1,260 4.22 0.0799
2021-05-18 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,628 556 10.96 1,209 0.83 0.0870
2021-02-17 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,072 2,429 91.90 1,199 66.76 0.0997
2020-11-19 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,643 -1,817 -40.74 719 -44.48 0.0722
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,460 2,129 91.33 1,295 133.33 0.1774
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,331 1,158 98.72 555 115.95 0.0799
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,173 -219 -15.73 257 8.90 0.0304
2019-11-15 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,392 202 16.97 236 8.26 0.0321
2019-08-12 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,190 1,190 218 0.0317
2018-08-13 2018-06-30 13F VERTEX PHARM COM 92532F100 0 -117 -100.00 0 -100.00
2018-05-14 2018-03-31 13F VERTEX PHARM COM 92532F100 117 0 0.00 18 0.00 0.0048
2018-02-14 2017-12-31 13F VERTEX PHARM COM 92532F100 117 80 216.22 18 200.00 0.0048
2017-11-14 2017-09-30 13F VERTEX PHARM COM 92532F100 37 37 6 0.0026
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.